Risk of Gynecomastia Exacerbation with Finasteride

Baseline Risk of Finasteride-Induced Gynecomastia

• Gynecomastia occurs in 0.5-2.2% of finasteride-treated patients versus 0.1-1.1% with placebo 1
• Breast tenderness affects an additional 0.4-0.7% of patients 1
• The American Society of Clinical Oncology and American Urological Association guidelines confirm gynecomastia as a consistent adverse event, with a 2-4% absolute increase in reported cases compared to placebo 2

Alternative Treatments

• For benign prostatic hyperplasia, alpha-blockers can be used as initial therapy, as recommended by guidelines 3

Clinical Decision Making

• Counsel patients explicitly about the 0.5-2.2% baseline risk of worsening gynecomastia and the potential for irreversible changes requiring surgery 1